The effect of the benzodiazepine antagonist flumazenil on regional cerebral blood flow in human volunteers.
The influence of the benzodiazepine antagonist flumazenil on regional cerebral blood flow (rCBF) was investigated in ten healthy, alert volunteers. The design was a randomized, placebo-controlled, double-blind, cross-over study. rCBF was measured by 133-Xe inhalation and single photon emission computerized tomography, SPECT, immediately before, and 5 and 35 min after intravenous injection of flumazenil 1.0 mg or placebo. In addition, mean arterial blood pressures or PaCO2, rCBF were analysed for changes in various regions of interest (RoI). No alterations were found either in the global CBF or in rCBF in RoI after flumazenil injection. The results showed that a clinically active dose of flumazenil did not directly affect the cerebral circulation in the normal brain and indicated absence of significant intrinsic activity of the drug.
Wolf
J
J
Department of Anaesthsia, Bispebjerg Hospital, Copenhagen, Denmark.
Friberg
L
L
Jensen
J
J
Hansen
P B
PB
Andersen
A R
AR
Lassen
N A
NA
D000328:Adult; D001794:Blood Pressure; D001921:Brain / Q000000981:diagnostic imaging; D002245:Carbon Dioxide / Q000097:blood; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D005442:Flumazenil / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010919:Placebos; D015899:Tomography, Emission-Computed, Single-Photon; D014980:Xenon Radioisotopes
D010919:Placebos; D014980:Xenon Radioisotopes; D002245:Carbon Dioxide; D005442:Flumazenil